176 related articles for article (PubMed ID: 9394855)
21. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
22. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
23. Hormonal therapy in early and advanced breast cancer.
Buzdar AU
Breast J; 2004; 10 Suppl 1():S19-21. PubMed ID: 14984485
[TBL] [Abstract][Full Text] [Related]
24. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
[TBL] [Abstract][Full Text] [Related]
25. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
26. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
[TBL] [Abstract][Full Text] [Related]
27. Role of anastrozole in adjuvant therapy for postmenopausal patients.
Buzdar AU
Semin Oncol; 2003 Oct; 30(5 Suppl 16):21-9. PubMed ID: 14613023
[TBL] [Abstract][Full Text] [Related]
28. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Dranitsaris G; Leung P; Mather J; Oza A
Anticancer Drugs; 2000 Aug; 11(7):591-601. PubMed ID: 11036964
[TBL] [Abstract][Full Text] [Related]
30. Clarification of anastrozole/megestrol acetate trial program design.
Howell A
J Clin Oncol; 2000 Dec; 18(24):4109. PubMed ID: 11118472
[No Abstract] [Full Text] [Related]
31. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
[TBL] [Abstract][Full Text] [Related]
32. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
[TBL] [Abstract][Full Text] [Related]
33. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
35. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Messori A; Cattel F; Trippoli S; Vaiani M
Anticancer Drugs; 2000 Oct; 11(9):701-6. PubMed ID: 11129731
[TBL] [Abstract][Full Text] [Related]
36. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Buzdar AU
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):6-10. PubMed ID: 11900212
[TBL] [Abstract][Full Text] [Related]
37. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Dombernowsky P; Smith I; Falkson G; Leonard R; Panasci L; Bellmunt J; Bezwoda W; Gardin G; Gudgeon A; Morgan M; Fornasiero A; Hoffmann W; Michel J; Hatschek T; Tjabbes T; Chaudri HA; Hornberger U; Trunet PF
J Clin Oncol; 1998 Feb; 16(2):453-61. PubMed ID: 9469328
[TBL] [Abstract][Full Text] [Related]
38. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Lavrenkov K; Man S; Geffen DB; Cohen Y
Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
[TBL] [Abstract][Full Text] [Related]
39. Advanced breast cancer updates on anastrozole versus tamoxifen.
Nabholtz JM;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):321-5. PubMed ID: 14623528
[TBL] [Abstract][Full Text] [Related]
40. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Robertson JF; Howell A; Buzdar A; von Euler M; Lee D
Breast Cancer Res Treat; 1999 Nov; 58(2):157-62. PubMed ID: 10674881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
